| Name | Repinotan |
| Description | Repinotan (BAY x 3702 free base) is an orally active, selective 5-HT1A receptor agonist that crosses the blood-brain barrier (BBB), exhibits neuroprotective activity, counteracts morphine-induced depression of ventilation in anesthetized rats, and may be used in studies of acute ischemic stroke and traumatic brain injury. |
| In vitro | Repinotan affects the anti-apoptotic protein Bcl-2, serotoninergic neurotransmitter glial growth factor S-100beta, nerve growth factor, and inhibits caspase-3 activity via MAPK and PKCα pathways [1]. |
| In vivo | Repinotan (1-100 μg/kg) induces a strong, dose-dependent reduction in infarct size in permanent and transient middle cerebral artery occlusion, as well as in traumatic brain injury paradigms[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Pure form: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Keywords | 5HTReceptor | 5-HT1A | 5HT Receptor |
| Inhibitors Related | Alverine citrate | Sevoflurane | Dapoxetine hydrochloride | Cefaclor monohydrate | Clozapine N-Oxide | 1,8-Cineole | Dopamine hydrochloride | Cloperastine hydrochloride | Mianserin hydrochloride | Trazodone hydrochloride | Cinchonidine | Doxepin hydrochloride |
| Related Compound Libraries | Pain-Related Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | ReFRAME Related Library | Neurotransmitter Receptor Compound Library | Drug Repurposing Compound Library | Neuroprotective Compound Library | Orally Active Compound Library | Clinical Compound Library | Bioactive Compounds Library Max | GPCR Compound Library | Human Metabolite Library |